Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of CT-P13 plus methotrexate in rheumatoid arthritis
2011-004468-31Phase 3Completed
- Sponsor
- Celltrion
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infliximab and infliximab-dyyb in rheumatoid arthritis (RA), sponsored by Celltrion. Primary endpoints: Long-term efficacy of CT-P13 plus methotrexate and Long-term safety of CT-P13 plus methotrexate. Started Nov 2011; status: completed.
02
Drugs
infliximabinfliximab-dyyb
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-004468-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004468-31.